Valuation: Moderna, Inc.

Capitalization 18.82B 16.3B 14.96B 14.07B 26.21B 1,794B 26.62B 178B 69.19B 867B 70.68B 69.14B 3,017B P/E ratio 2026 *
-5.49x
P/E ratio 2027 * -10x
Enterprise value 15.26B 13.22B 12.13B 11.41B 21.25B 1,455B 21.59B 144B 56.11B 703B 57.31B 56.07B 2,446B EV / Sales 2026 *
7.31x
EV / Sales 2027 * 6.59x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-8.04%
1 week+0.53%
Current month+0.53%
1 month-2.77%
3 months-9.67%
6 months+71.26%
Current year+60.87%
1 week 43.9
Extreme 43.9
51.9
1 month 43.9
Extreme 43.9
59.48
Current year 29.81
Extreme 29.81
59.55
1 year 22.28
Extreme 22.28
59.55
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 62 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
06-01Fiscal year

General Counsel

5,377 0.0014%
06-01Fiscal year

Chief Financial Officer

6,147 0.0015%
06-01Fiscal year

Chairperson

23,052 0.0058%
Change 5d. change 1-year change 3-years change Capi.($)
-8.04%+0.53%+72.76%-62.62% 18.82B
+1.07%+3.36%+28.84%-15.06% 64.65B
+0.58%+3.69%+60.37%+210.79% 57.37B
-0.74%+34.00%+34.00%+34.00% 39.87B
+5.92%+1.35%-59.53%-68.18% 33.6B
-0.57%-0.34%+46.73%-34.84% 28.84B
+1.13%+5.83%+48.87%+65.91% 20.45B
+0.26%-8.10%+4.72%+109.86% 16.99B
+0.27%+1.00%+45.38%+107.72% 16.35B
+0.42%+2.04%+75.06%+321.51% 13.24B
Average +0.03%+0.57%+35.72%+66.91% 31.02B
Weighted average by Cap. +0.46%+1.26%+32.93%+55.56%

Financials

2026 *2027 *
Net sales 2.09B 1.81B 1.66B 1.56B 2.91B 199B 2.95B 19.71B 7.67B 96.19B 7.84B 7.67B 334B 2.51B 2.18B 2B 1.88B 3.5B 239B 3.55B 23.73B 9.23B 116B 9.43B 9.23B 403B
Net income -3.4B -2.95B -2.7B -2.54B -4.74B -324B -4.81B -32.15B -12.51B -157B -12.78B -12.5B -546B -1.84B -1.59B -1.46B -1.38B -2.56B -175B -2.6B -17.38B -6.76B -84.79B -6.91B -6.76B -295B
Net Debt -3.56B -3.08B -2.83B -2.66B -4.96B -339B -5.03B -33.62B -13.08B -164B -13.36B -13.07B -570B -2.27B -1.97B -1.81B -1.7B -3.17B -217B -3.21B -21.47B -8.36B -105B -8.54B -8.35B -364B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
05/06/26 47.44 $ -8.04% 6,084,113
04/06/26 51.59 $ +5.16% 6,709,675
03/06/26 49.06 $ +7.49% 6,934,371
02/06/26 45.64 $ -0.91% 5,690,074
01/06/26 46.06 $ -2.39% 6,177,795
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
47.44USD
Average target price
43.20USD
Spread / Average Target
-8.94%

Quarterly revenue - Rate of surprise